General Anesthesia Drugs Market is expected to reach US$ 6.7 Billion at a CAGR of 3.4% by 2032 | FMI

 The General Anesthesia Drugs Market is anticipated to reach a value of US$ 4.7 billion by the end of 2022 and to grow at a CAGR of 3.4% to US$ 6.7 billion by 2032. Propofol is the most popular drug class right now, with a market share of about 25.6% in 2021, according to a recent study by Future Market Insights.


Gain complete access to the report @ https://www.futuremarketinsights.com/reports/general-anesthesia-drugs-market

Increasing geriatric population coupled with rising incidences of chronic illnesses have resulted in a surge in surgeries. With an increasing elderly population, a greater number of surgeries are conducted resulting in a high demand for anesthesia drugs. Furthermore, the healthcare expenditure is rising in developing and developed countries. Since, anesthesia is usually covered by health insurance for all medical procedures, the out-of-pocket cost for anesthesia for patients with medical insurance is around 10% to 50%. Hence, health insurance is advantageous for the general anesthesia market.

Ambulatory anesthesia delivers faster recovery from general anesthesia drugs, patients can leave the hospital earlier while also offering tremendous benefits to third-party payers, hospitals, healthcare providers, and patients. Again, there’s a surge in the number of ambulatory surgeries owing to constant progress in general anesthesia drugs and different techniques, along with the easy availability of short-acting anaesthetics with less side effects. This bodes well for the target market.

The development of specific targeted drugs, the availability of technologically sophisticated drug delivery devices, and rising clinical trials for the development of general anesthesia drugs as well as expanding portfolio of the general anesthesia drugs will lead to the expansion of the general anesthesia drugs market during the forecast period.

“Rising geriatric population coupled with increasing incidences of chronic diseases lead to a surge in the number of surgeries performed which in turn augments the sales of general anesthesia drugs in the global market during the forecast period,” says an FMI analyst.  

Key Takeaways:

  • Increasing investment in clinical trials for the development of general anesthesia drugs will strengthen the market prospects for the same.
  • Side effects like amnesia, respiratory depression, high blood pressure, and others may negatively impact the market growth. 
  • The U.S general anesthesia drugs market will record a 2.4% CAGR during the projected period.
  • Growing cancer cases drives the growth of the general anesthesia drugs market in China.
  • Propofol general anesthesia drugs segment will grow at a 4.2% CAGR.
  • Intravenous route of administration will grow at a 3.6% CAGR.

Competitive Landscape 

Baxter International Inc., AstraZeneca, AbbVie Inc., B. Braun Melsungen AG, Fresenius SE & Co. KgaA, Pfizer, Hospira Inc., Aspen Pharmacare Holdings Limited, Hikama Pharmaceuticals plc, Abbott Laboratories, Avet Pharmaceuticals, Inc, Piramal Enterprises Limited, Par Pharmaceutical, Teva Pharmaceuticals, Viatris/Mylan, Novartis AG, GlaxoSmithKline plc, Gilead Sciences, Inc., Sanofi, Akorn, Apotex, and Heritage Pharmaceuticals Inc., among others are some of the major players in the Neuromuscular Blocking Drugs Market profiled in the full version of the report.

Leading market players are concentrating product development and new product releases to cater to the consumer demand. These businesses employ tactics like mergers, acquisitions, partnerships, and collaborations to expand their consumer base.

Key Market Segments Covered in General Anesthesia Drugs Industry Research

By Drug Class:

  • Propofol
  • Sevoflurane
  • Dexmedetomidine
  • Desflurane
  • Remifentanil
  • Midazolam
  • Others – (Sufentanil, Fentanyl, Ketamine, Isoflurane, Thiopental etc.)

By Route of Administration:

  • Intravenous Anesthesia
  • Inhaled Anesthesia

By End User:

  • Hospitals
  • Ambulatory Surgical Centers
  • Specialty Clinics

Comments

Post a Comment

Popular posts from this blog

Pet Diabetes Care Devices Market Report | Size, Growth, Demand, Scope and Forecast to 2032

  The global  Pet Diabetes Care Devices Market  is expected to grow at a  6.5%  CAGR, reaching  US$ 4 billion  by 2032, up from  US$ 2 billion  in 2021. “The number of pets with diabetes, the number of adopted pets, and the number of overweight pets are all driving the market forward.” Get Full Access @ https://www.futuremarketinsights.com/reports/pet-diabetes-care-devices-market The domestication of animals is leading to a lack of insulin production in them. The limited flow of glucose to the cell can be termed diabetes. This chronic disease is a major concern for pet owners and needs to be taken care of. This concern leads to the expansion of the pet diabetes care devices market. Devices like the alphatrak blood glucose meter are in use as they help the pet owners monitor the pet’s health. The increased number of people adopting pets and then domesticating them around in their households, treating and caring for them as f...
Read more

Human Immunodeficiency Virus Type 1 (HIV 1) Market Opportunity, Competitive Analysis, Future Prospects to 2033

Image
  The global Human Immunodeficiency Virus Type 1 (HIV 1) Market is predicted to exceed a remarkable valuation of US$ 34.83 Billion in 2023, with a compound annual rate of growth (CAGR) of 6% estimated from 2023 to 2033. The Institute for Health Metrics and Evaluation attributes the industry's growth to the soaring incidence rate of HIV-1 infection, which, unlike the deaths caused from this viral illness, has not updated substantially over time. Get Full Access @ https://www.futuremarketinsights.com/reports/human-immunodeficiency-virus-type-1-hiv1-market It affected approximately 37 million people worldwide. Furthermore, antiretroviral therapeutic interventions for disease management are only available to half of this population. HIV-1 is the more common of the two types of human immunodeficiency virus, accounting for approximately 96% of all infections globally. The prevalence of HIV is rising at an alarming rate. The World Health Organization (WHO) estimates that 33.0 million...
Read more

Clostridium Diagnostics Market in US is anticipated to secure a market value worth US$ 2.7 Billion by 2032 | FMI

Image
  The global Clostridium Diagnostics Market is expected to grow at a CAGR of 12.2% during the forecast period, from US$ 2.5 billion in 2022 to US$ 7.8 billion by 2032. The market grew at a CAGR of 13.6% between 2015 and 2021. The rising prevalence of clostridium-related diseases, as well as increased campaigns to educate people about the condition, are driving the market growth. To learn more about this report @ https://www.futuremarketinsights.com/reports/clostridium-diagnostics-market here has been an increased focus of players in the market to offer vaccines, which can augment the market size in the forecast period. For instance, in March 2022, Japan launched a new center, with a budget of US$ 1.6 Billion, to support vaccine and drug projects as a part of a larger scheme to tackle infectious diseases. SCARDA will be in charge of establishing a flagship R&D site for innovative collaborations and controlling funds for R&D projects. Awareness camp...
Read more